Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CEACAM1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CEACAM1 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View CEACAM1 Products |
| Gene Delivery | CEACAM1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and cell-based functional assays. |
View CEACAM1 Products |
| Benchmark Ab | Anti-CEACAM1 (Sequence of MK-6018) Recombinant positive control for binding and blockade assays. |
View CEACAM1 Products |
| Validator | CEACAM1 siRNA Set For target knockdown verification and specificity controls. |
View CEACAM1 Products |
| Related Target A | CEACAM5 Critical homolog for cross-reactivity and off-target safety counter-screening. |
View CEACAM5 Products |
| Related Target B | PD-L1 Synergistic immune checkpoint pathway partner often co-targeted in combination therapies. |
View PD-L1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| CEACAM family cross-reactivity screening (avoiding CEACAM3/5/6 off-target binding) | Homolog panel proteins (CEACAM3, CEACAM5, CEACAM6) strictly verified by mass spectrometry and sequence analysis. |
| Distinguishing homophilic vs. heterophilic interaction blockade | Monomeric and dimeric Fc-fusion protein configurations available to mimic physiological ligand presentation. |
| Lack of standardized clinical references | Recombinant benchmark antibodies (based on clinical candidate sequences) included to calibrate assay sensitivity. |
| False positives in antibody binding assays | Sequence-verified target-specific siRNA sets included for knockout/knockdown verification in target-expressing cells. |
Live CEACAM1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CEACAM1 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to multi-specific immune checkpoint inhibitors and antibody-drug conjugates (ADCs). As first-generation therapies reach the clinic, the next wave of R&D is targeting the dual role of CEACAM1 as both an immune-inhibitory receptor on T/NK cells and a tumor-promoting adhesion molecule in epithelial malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | Merck (MK-6018), ImmuneOnco | Solid Tumors, Melanoma, NSCLC | Blockade Assay (Requires high-purity, low-endotoxin CEACAM1 ECD-Fc to evaluate ligand interference) |
| Bispecific / Multispecific | Academic & Biotech Consortiums | Refractory Solid Tumors | Dual-binding Affinity (Requires co-expression systems and high-purity PD-L1 or other co-target proteins) |
| Antibody-Drug Conjugate (ADC) | Preclinical Pipelines | Colorectal Cancer, Pancreatic Cancer | Internalization Assay (Requires stable cell lines generated via high-titer CEACAM1 Lentivirus) |